SGLT-2 inhibitors are the newest diabetes drug class on the market, and to date research on their long-term safety has been lacking. The American Heart Association has published the results of a major meta analysis which reviewed all the available trials and studies. The researchers found that use of SGLT-2 inhibitors led to a 20% reduction in death from cardiovascular disease and stroke. Hypoglycemia and serious adverse events were also less likely to occur with SGLT-2 inhibitors than with controls. Read more